Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by mayfieldfrankon Mar 31, 2017 5:35pm

295 Views

Post# 26060895

RE:RE:New Update

Naw. I think its just one of those medical companies thats going to take its normal course to get all the I's dotted amnd T's crossed before you'll see some big results. Think of it. Its a great idea and if the product can do what they want it to, think of the money the medical system could save. No doubt there will be hic-cups and I'm sure more shares issued as time goes on. I for one am going to hang on to this one.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages